NeuMoDx Molecular
- Company typePrivate
- Founded2012
- HeadquartersAnn Arbor, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What NeuMoDx Molecular does
NeuMoDx Molecular, Inc. is a molecular diagnostics company founded in 2012 and headquartered in Ann Arbor, Michigan, that developed automated sample-to-result systems for clinical molecular diagnostic (MDx) testing. The company's core product platform integrated nucleic acid extraction, amplification, and detection into a closed, cartridge-based instrument workflow intended for hospital and reference laboratory settings, reducing hands-on time relative to legacy multi-step MDx protocols.
The company was privately held and funded through a series of equity rounds totaling approximately $66M, with participation from healthcare-focused venture investors including Arboretum Ventures, Baird Capital, Pfizer Venture Investments, Clarevia Ventures, and Wolverine Venture Fund. Jeff Williams served as Chairman and CEO. The company operated with a focused organization of 11–50 employees, consistent with an instrument-and-consumables commercialization stage prior to exit.
In 2021, NeuMoDx was acquired by Qiagen, a global molecular diagnostics and sample technologies provider, and now operates as a wholly owned subsidiary within Qiagen's diagnostics portfolio. The standalone business model relied on instrument placement paired with recurring cartridge/consumable revenue, the standard razor-and-blade economics of the clinical MDx industry, though specific pricing, contract structures, and customer counts are not disclosed in the available source data. The current public web presence at neumodx.com is a loader/verification page with no substantive product, pricing, or operational detail.
NeuMoDx Molecular firmographics
Firmographics- Name
- NeuMoDx Molecular
- Website
- https://neumodx.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
NeuMoDx Molecular industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industry
- Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)
Keywords
Where NeuMoDx Molecular is headquartered
LocationHeadquarters
- HQ city
- Ann Arbor
- HQ country
- United States
- HQ region
- North America
Markets served
NeuMoDx Molecular business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
NeuMoDx Molecular product offering
Product offeringCore offering
NeuMoDx Molecular develops molecular diagnostic (MDx) testing solutions for clinical laboratories. The company focuses on building automated systems and assays that enable molecular testing workflows used by healthcare and laboratory customers.
Differentiator
Problem solved
Functional benefit
Products and services
- Molecular diagnostic (MDx) testing solutions
Companies that use NeuMoDx Molecular
Customer profileIdeal customer profiles1 record
NeuMoDx Molecular technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
NeuMoDx Molecular partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights2 records
NeuMoDx Molecular competitors and assessment
Company assessmentBroad incumbents
- Roche Diagnostics (cobas): Roche's cobas molecular diagnostics platform competes with NeuMoDx in centralized and high-volume hospital lab settings, and Roche also owns GenMark Diagnostics for a similar automated molecular footprint.
- Becton Dickinson (BD): BD's molecular diagnostics business, including the BD MAX system, directly competes with NeuMoDx in automated sample-to-answer PCR testing for clinical laboratories and hospitals.
- Abbott (m2000 / Alinity m): Abbott's m2000 and Alinity m molecular diagnostics platforms compete with NeuMoDx in central lab and hospital molecular testing, particularly in infectious disease and viral load monitoring.
- Qiagen (parent company): Qiagen is the strategic acquirer of NeuMoDx and operates its own molecular diagnostics portfolio (QIAstat-Dx, etc.), making it both the parent and a meaningful internal benchmark for NeuMoDx's automated PCR roadmap.
Direct peers
- GenMark Diagnostics: GenMark (acquired by Roche) developed the ePlex automated molecular diagnostics platform, a close peer to NeuMoDx in offering sample-to-answer PCR-based testing for hospital labs.
- bioMérieux (BioFire): bioMérieux's BioFire FilmArray system is a leading fully-automated molecular diagnostics platform for syndromic testing, directly comparable to NeuMoDx's automated PCR value proposition in clinical settings.
- Hologic (Panther): Hologic's Panther system is a fully-automated molecular diagnostics platform with a similar value proposition to NeuMoDx for women's health, infectious disease, and hospital lab testing customers.
- Luminex (DiaSorin): Luminex (acquired by DiaSorin) developed the ARIES and VERIGENE automated molecular diagnostics systems, providing a directly comparable platform to NeuMoDx in the hospital molecular lab segment.
- Cepheid: Cepheid (a Danaher subsidiary) is the leading fully-automated molecular diagnostics PCR platform competitor with its GeneXpert system, directly comparable to NeuMoDx's automated PCR platform in serving hospital and clinical lab customers.
Emerging players
- T2 Biosystems: T2 Biosystems is an emerging molecular diagnostics company developing rapid, automated molecular detection platforms for clinical applications, partially overlapping with NeuMoDx's automated testing focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
NeuMoDx Molecular social profiles
Digital presenceNeuMoDx Molecular financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuMoDx Molecular leadership team
Management profileNumber of profiles
Profiles1 record
NeuMoDx Molecular funding detail
Funding detailFunding overview
Funding rounds5 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuMoDx Molecular M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuMoDx Molecular
What does NeuMoDx Molecular do?
NeuMoDx Molecular develops molecular diagnostic (MDx) testing solutions for clinical laboratories. The company focuses on building automated systems and assays that enable molecular testing workflows used by healthcare and laboratory customers.
Is NeuMoDx Molecular a public or private company?
NeuMoDx Molecular is a private company. It is classified as corporate owned and is currently acquired.
When was NeuMoDx Molecular founded?
NeuMoDx Molecular was founded in 2012. It employs 11 to 50 people.
Where is NeuMoDx Molecular based?
NeuMoDx Molecular is headquartered in Ann Arbor, United States, in the North America region.
Who are NeuMoDx Molecular's main competitors?
Broad incumbents on record are Roche Diagnostics (cobas), Becton Dickinson (BD), Abbott (m2000 / Alinity m) and Qiagen (parent company). Direct peers are GenMark Diagnostics, bioMérieux (BioFire), Hologic (Panther), Luminex (DiaSorin) and Cepheid. T2 Biosystems is listed as an emerging player.
Does NeuMoDx Molecular have an API?
No public API is recorded for NeuMoDx Molecular.
What industry is NeuMoDx Molecular in?
NeuMoDx Molecular's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAHAOAI, Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges). Its NAICS code is 325413 and its SIC code is 2835.